Screening for autonomic neuropathy using validated non-invasive scale among diabetes patients treated in the selected primary health centres of Puducherry, India: an operational research
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20194006Keywords:
Diabetes, Autonomic neuropathy, Primary health centre, Non-communicable diseasesAbstract
Background: Diabetes autonomic neuropathy (DAN) is a complication of diabetes which has direct implications on the mortality of diabetes patients. American Diabetes Association (ADA-2017) guidelines recommend early recognition and treatment of DAN. In this regard, we conducted a study among diabetic patients treated in the selected PHCs of Puducherry to determine the proportion with DAN and to assess the factors associated with DAN.
Methods: A cross-sectional analytical study was conducted among diabetics and information on socio-demographic details, morbidity and behavioural risk factors were elicited using semi-structured interview schedule. The COMPASS-31 questionnaire was administered to assess the autonomic neuropathy symptoms. The data was captured using EpiCollect mobile app and analysed using Stata 12.0 software. The proportion of DAN was expressed as percentage with 95% confidence interval. The association between independent factors and DAN was assessed using multivariate generalized linear models. The prevalence ratio with 95% CI was used to express the strength of association.
Results: Of the total 303 individuals with diabetes, 32 {10.6% (95% CI: 7.3%-14.6%)} were screened positive for autonomic neuropathy using COMPASS-31 scale. The number of individuals with diabetes who needed to be screened (NNS) for finding one with autonomic neuropathy was 10 (303/32).
Conclusions: One in ten individuals with diabetes was screened positive for autonomic neuropathy. With good yield, there is need for including autonomic neuropathy screening as a component in the comprehensive care provided to diabetes patients in the primary health centres.
References
Diabetes Atlas. International Diabetes Federationl, 2017. Available at: URL:http://www.idf.org/diabete satlas. Accessed on 19 January 2017.
World Health Organization, 2016. Global report on diabetes. France: WHO 2016.
Low PA, Benrud-Larson LM, Sletten DM, Opfer-Gehrking TL, Weigand SD, O'Brien PC, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care. 2004;27(12):2942-7.
Aggarwal S, Tonpay PS, Trikha S, Bansal A. Prevalence of autonomic neuropathy in diabetes mellitus. Curr Neurobiol. 2011;2(2):101-5.
Koo BK. Screening of autonomic neuropathy in patients with type 2 diabetes. Diabetes Metab J. 2014;38(5):346-8.
Verrotti A, Prezioso G, Scattoni R, Chiarelli F. Autonomic neuropathy in diabetes mellitus. Front Endocrinol. 2014;5(1):1-15.
Zilliox L, Peltier AC, Wren PA, Anderson A, Smith AG, Singleton JR, et al. Assessing autonomic dysfunction in early diabetic neuropathy. Neurol. 2011;76(12):1099-105.
Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553-79.
Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care. 2003;26(6):1895-901.
Ewing DJ, Campbell IW, Clarke BF. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. Ann Intern Med. 1980;92(2):308-11.
American diabetes association, 2017. Standards of medical care in diabetes-2017. Diabetes Care. 2017;40(1):38-94.
Levy V, Bordier L, Calvet J-H, Herisse GL, Bauduceau B. Potential budgetary impact of large scale screening of small fiber neuropathy in the follow-up of patients with type 2 diabetes in France. J Diabetes Metab. 2015;6(10).
Yajnik CS, Kantikar V, Pande A, Deslypere J-P, Dupin J, Calvet JH, et al. Screening of cardiovascular autonomic neuropathy in patients with diabetes using non-invasive quick and simple assessment of sudomotor function. Diabetes Metab. 2013;39(2):126-31.
Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated composite autonomic symptom score. Mayo Clin Proc. 2012;87(12):1196-201.
Office of the Registrar General and Census Commissioner, Ministry of Home Affairs, Government of India. Puducherry (Pondicherry) District : Census 2011 data. 2011 Available at: http://www.census2011.co.in/census/ district/482-puducherry.html. Accessed on 9 September 2017.
Gupta SK, Gupta SK, Singh Z, Purty AJ, Vishwanathan M. Diabetes prevalence and its risk factors in urban Pondicherry. Int J Diab Dev Ctries. 2009;29(4):166-9.
Ghorpade AG, Maigi MS, Sarkar S, Kar SS, Rov G, Das AK, et al. Diabetes in rural Pondicherry, India: a population-based study of the incidence and risk factors. WHO South-East Asia J Public Health. 2013;2(3):149-55.
Bharati DR, Pal R, Kar S, Rekha R, Yamuna TV, Basu M, et al. Prevalence and determinants of diabetes mellitus in Puducherry, South India. J Pharm Bioallied Sci. 2011;3(4):513-8.
Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes. 2014;5(1):17-39
O’Brien IA, McFadden JP, Corrall RJ. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med. 1991;79:495-502.
Ziegler D, Gries FA, Spüler M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic cardiovascular autonomic neuropathy multicenter study group. J Diabetes Complications. 1992;6:49-57.
Kempler P, Tesfaye S, Chaturvedi N, Stevens LK, Webb DJ, Eaton S, et al. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med. 2002;19:900-9.
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93.
Valensi P, Paries J, Attali JR. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications- the French multicentre study. Metabolism. 2003;52:815-20.
